Joanna Wolak, Endlyz Therapeutics CEO
March 31, 2025 12:01 AM EDT
Financing
Startups

Ex­clu­sive: SV Health de­buts Parkin­son's biotech with back­ing from Ab­b­Vie and oth­ers

Kyle LaHucik

Senior Reporter

SV Health In­vestors, fresh off a $250 mil­lion fund for de­men­tia-fo­cused biotechs, has un­veiled its lat­est ef­fort, this time to ad­vance new …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
ENDPOINTS CAREERS

Vice President, Biology & Translational Research

Gondolabio

Palo Alto, CA, USA

TRENDING NOW

Fir­ings sweep across FDA as for­mer lead­ers lament the gut­ting of drug agency

Big am­bi­tions at Mer­ck and As­traZeneca — along with a few gi­ant pit­falls — re­shape top ranks of the R&D 15

RNA edit­ing start­up rais­es $155M to bring liv­er and lung dis­ease ther­a­py in­to clin­ic

Sanofi con­tin­ues its bet on R&D by poach­ing GSK’s head of de­vel­op­ment

What’s next af­ter Marks? At FDA, ques­tions over more top ex­its and fu­ture vi­sion for drug agency

sponsored

End­points we­bi­nar: In­side the “One Lon­za” strat­e­gy: Re-en­gi­neer­ing the fu­ture of CD­MO

A service from the Financial Times